Global private equity and venture capital news and research

Venture capital-backed Versartis soars after IPO

24 Mar 2014

graph_positive_170sqVenture capital-backed biopharmaceutical company Versartis has raised nearly $126m via an IPO, which was priced at $21 per share.

Shares in Versatilis soared nearly 50 per cent on the Nasdaq exchange on Friday to close at $31.37.

The company sold 6m shares and granted the underwriters a 30-day option to buy up to 900,000 shares at the IPO price.

Versatilis is backed by include Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences.

Last October Sofinnova led a $20m Series D round for Versartis to help the company prepare for an international Phase 3 pediatric trial of VRS-317, a treatmet for patients with growth hormone deficiency.

Copyright © 2014 AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016